Abeona Narrows Loss as ZEVASKYN Treatments Rise

The Tip Desk · November 9, 2026 · 3 min read

Net ZEVASKYN revenue was $13.5 million in the third quarter, and the company completed six treatments as its qualified-center network reached eight sites.

Abeona Therapeutics Inc. (ABEO), a commercial-stage biopharmaceutical company, reported net ZEVASKYN revenue of $13.5 million for the quarter ended September 30, 2026, an 18% sequential increase from $11.4 million in the second quarter.

The sequential gain followed a 31% second-quarter rise from $8.7 million in the first quarter. Six patient treatments were completed in the third quarter, versus five in the second and three in the first; cumulative treatments since launch totaled 15.

Revenue was not recognized for one third-quarter treatment because the associated batch did not meet the identity-assay release criterion, the company said.

The qualified treatment center network expanded to eight sites from seven in the second quarter and six in the first. Children’s Hospital of Philadelphia and the University of Texas Medical Branch completed their first ZEVASKYN treatments, lifting the number of centers with treatment experience from two to four. University of Florida Health in Gainesville was activated in September as the eighth site, and Cincinnati Children’s had been activated in July.

New Technology Add-On Payment status for ZEVASKYN became effective October 1, 2026, under CMS’s fiscal year 2027 Hospital Inpatient Prospective Payment System Final Rule. The company said the designation is expected to help support patient access and hospital adoption among eligible Medicare beneficiaries, who represent approximately 10 percent of RDEB patients.

Cost of sales was $5.7 million, compared with $4.2 million in the second quarter. Research and development expenses were $3.7 million, down from $5.0 million in the second quarter; first-quarter R&D of $9.6 million had included a $7.0 million one-time in-licensing cost for ABO-701. Selling, general and administrative expenses were $17.1 million.

Net loss narrowed to $4.8 million, or $0.08 a share, from a $20.2 million, or $0.35 a share, loss in the second quarter.

Cash, cash equivalents and short-term investments were $134.9 million as of September 30, 2026, compared with $146.8 million at June 30. That balance excludes $30 million of gross proceeds from a private placement completed after quarter-end. The company said it intends to use net proceeds for general corporate purposes, including pipeline development and ZEVASKYN commercialization.

In a separate announcement, Abeona acquired APT-1011, now ABO-801, from Ellodi Pharmaceuticals. The asset is a Phase 3-ready, once-daily oral disintegrating tablet of fluticasone propionate in development for eosinophilic esophagitis. Abeona issued $20 million of common stock at closing, with no upfront cash. Ellodi is eligible for $30 million upon FDA approval of ABO-801, up to an additional $30 million on specified sales milestones, and tiered royalties on net sales ranging from low to mid teen percentages.

Chief Executive Officer Vish Seshadri said maximizing the opportunity for ZEVASKYN remains the company’s number one priority and that the APT-1011 acquisition is a step toward a diversified commercial-stage company.

Ultragenyx received FDA approval in September of FAYUVI for Sanfilippo Syndrome Type A, a program Abeona previously advanced before licensing it in May 2022. Under that agreement, Abeona is eligible for certain commercial milestones and tiered royalties of up to 8 percent on future product sales.